Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways

number of downloads : ?

Use this link to cite this item : https://ir.lib.shimane-u.ac.jp/53656

language	eng
Author	Mitsui Yozo 1 Department of Urology, Shimane University Faculty of Medicine, Enya-cho, Izumo, Japan 2 Department of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco, California, USA Hirata Hiroshi Department of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco, California, USA Arichi Naoko Department of Urology, Shimane University Faculty of Medicine, Enya-cho, Izumo, Japan Hiraki, Miho YASUMOTO, Hiroaki Chang Inik Department of Oral Biology, Yonsei University College of Densitry, Seoul, South Korea Fukuhara Shinichiro Department of Urology, Osaka University Graduate School of Medicine, Suita, Japan Yamamura Soichiro Department of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco, California, USA Shahryari Varahram Department of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco, California, USA Deng Guoren Department of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco, California, USA Saini Sharanjot Department of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco, California, USA Majid Shahana Department of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco, California, USA Dahiya Rajvir Department of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco, California, USA Tanaka Yuichiro Department of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco, California, USA Shiina, Hiroaki
Subject	bone morphogenetic protein 2; renal cell carcinoma; DNA methylation; molecular marker
Journal Title	ONCOTARGET
Volume	6
Issue	11
Start Page	9577
End Page	9591
ISSN（Online）	1949-2553
Published Date	2015-04-20
DOI	10.18632/oncotarget.3445
PubMed ID	25797254
Publisher	IMPACT JOURNALS LLC
NII Type	Journal Article
OAI-PMH Set	Faculty of Medicine
Remark	Address all correspondence and requests for Yozo Mitsui, MD, PhD, Departments of Urology, Shimane University Faculty of Medicine, 89-1 Enya-cho, 693-8501 Izumo, Japan. E-mail: mitsui@med.shimane-u.ac.jp. We thank Dr. Roger Erickson for his support and assistance with the preparation of the manuscript. This research study was supported by the National Center for Research Resources of the NIH through Grant Number RO1CA130860 and VA Merit Review and VA Program Project.